Detected on Tuesday 27 October, 15h27
Xolair devient substituable en officine par son biosimilaire Omlyclo
L'omalizumab (Xolair) devient substituable en pharmacie par son biosimilaire Omlyclo, une évolution de la délivrance de ce traitement.
In brief
Health event (severity: info) nationwide, first detected on 27 October 2026 at 15:27. Reported by 1 source (1 article), last updated on 27 October 2026 at 15:27.
- Category
- Health
- Severity
- Info
- Place
National
- Detected
- 27 Oct, 15h27
- Updated
- 27 Oct, 15h27
- Reference
- no.3393
1 article · 1 source · no rated outlet covers this topic yet (public service, agencies, official accounts…)
Angle comparison
A comparison is written as soon as the event is covered by at least two sides (left, centre, right).
Lire les sources · 1 article, 1 source
- 15h27Le Moniteur des pharmaciesWirevia Google Actualités France27 OctOmalizumab : Xolair devient substituable en officine par son biosimilaire Omlyclo - Le Moniteur des pharmacies
Omalizumab : Xolair devient substituable en officine par son biosimilaire Omlyclo Le Moniteur des pharmacies
Further reading
Organisations cited
Keywords
#médicament · #biosimilaire · #Xolair · #pharmacie
Go up the thread
People and organisations cited